| Identification | Back Directory | [Name]
Gadoteridol | [CAS]
120066-54-8 | [Synonyms]
0))-
prohance
SQ 32692
gd-hp-do3a
gadotridol
Gadoteridol
ICG-Hydrazide
ICG-Maleimide
disulfo-ICG-NHS
gadolinium-hp-do3a
GADOTERIDOL (500 MG)
Gadoteridol USP/EP/BP
diSulfo-ICG Maleimide
diSulfo-ICG Hydrazide
triSulfo-Cy5.5 hydrazide
triSulfo-Cy5.5 Maleimide
1-Chloro-3-dodecylbenzene
Anti-6,6'-disulfo LacNAc Monoclonal Antibody (L4L4-8)
2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3-ol
to(3-)-n(sup1),n(sup4),n(sup7),n(sup10),o(sup1),o(sup4),o(sup7),o(sup1
Gadolinium 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1,4,7-triacetate
gadolinium,(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triaceta | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C17H29GdN4O7 | [MDL Number]
MFCD20037423 | [MOL File]
120066-54-8.mol | [Molecular Weight]
558.68 |
| Hazard Information | Back Directory | [Uses]
Diagnostic aid (paramagnetic). | [Definition]
ChEBI: A non-ionic gadolinium chelate having a macrocyclic tetraamine framework. It is used as a paramagnetic contrast agent in magnetic resonance imaging (MRI). | [Brand name]
Prohance (Bracco). | [General Description]
Gadoteridol is a nonionicclear, colorless to slightly yellow, gadolinium-based contrastagent indicated to visualize lesions with abnormal vascularityin the CNS, head, and neck. It is a hypertonic solutionwith an osmolality of 2.2 times that of plasma. Clinical enhancementof images occurs primarily when using T1-weighted sequences. |
|
|